Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an inhaled therapy replace a daily pill for PAH?

NCT ID NCT07759804

Disease control Sponsor: Liquidia Technologies, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether adults with pulmonary arterial hypertension (PAH) can safely switch from selexipag, a pill taken by mouth, to LIQ861, an inhaled form of treprostinil. Participants stop selexipag on day one and start taking LIQ861 four times a day using a handheld inhaler, with doses adjusted based on how well they tolerate it. The study tracks side effects, walking distance, a blood marker of heart strain, and reported symptoms over 16 weeks. The goal is to see if this switch is a safe and tolerable option for managing PAH.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LIQ861 (treprostinil) inhalation powder, taken four times daily via a handheld dry powder inhaler
What this could lead to
If successful, this could offer people with PAH a new way to manage their condition by switching from a daily pill to an inhaled treatment, potentially with fewer side effects.
What could go wrong
This is a small, open-label study (20 people) focused on safety and tolerability, not effectiveness. It may not show clear benefits, and some people may not tolerate the switch or the inhaled drug.
Why investors are watching

Liquidia is testing LIQ861, an inhaled form of treprostinil, in patients with pulmonary arterial hypertension who switch from an oral drug called selexipag. This small Phase 4 study matters because it could show that LIQ861 is a safe and tolerable alternative for patients already on a similar therapy, which would broaden its use beyond its current approved setting. For a small company, a positive safety and tolerability result in this switching population could support wider adoption and strengthen its position in the PAH market.

If it works: If the study shows LIQ861 is well tolerated when patients switch from selexipag, doctors may feel more comfortable prescribing it, potentially expanding the drug's patient base. A positive readout could also support regulatory discussions or label expansion, giving Liquidia a stronger commercial story.

If it fails: If the trial shows poor tolerability or safety issues, it could limit LIQ861's use in this switching population and hurt the company's credibility. Trials often fail to meet their goals, and a negative result could delay broader adoption and weigh on the company's prospects.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female 18 to 80 years of age * Documented findings on right heart catheterization consistent with a diagnosis of WHO Group 1 pulmonary arterial hypertension of one of the following subtypes: idiopathic PAH; heritable PAH; drug- or toxin-induced PAH; PAH associated with connective tissue disease; or PAH associated with simple congenital systemic-to-pulmonary shunts repaired at least 1 year previously * Receiving selexipag at any dose between 200 and 1600 mcg twice daily for at least 90 days, and willing and able to transition from selexipag to LIQ861 due to unsatisfactory clinical response or tolerability issues * May be receiving up to 2 additional approved non-prostacyclin oral PAH therapies at a stable dose and regimen, planned to continue unchanged for the duration of the study * New York Heart Association Functional Class II or III * Able to demonstrate correct use of the dry powder inhaler Exclusion Criteria: * Pulmonary hypertension in WHO Group 2, 3, 4, or 5, or a WHO Group 1 subtype not listed in the inclusion criteria * Clinically significant left-sided heart disease by echocardiography, including left ventricular ejection fraction ≤ 45%, left atrial volume index \> 48 mL/m², or hemodynamically significant valvular disease * Symptomatic coronary artery disease within the previous 6 months * Prior atrial septostomy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary arterial hypertension (PAH) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary arterial hypertension (PAH)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Southeastern Cardiology Associates

    Columbus, Georgia, 31904, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.